Page 10 - JCTR-10-6

320 Hanno et al.ǀ Journal of Clinical and Translational Research 2024; 10(6): 317-324
different categories. The significance of the obtained results was Table 4 shows different regimens for previous Helicobacter
judged at the 5% level. pylori treatment. Among the 483 experienced patients, 119
(24.64%) of them received PPI, amoxicillin and clarithromycin,
3. Results and 154 (31.88%) patients received PPI, amoxicillin and
Table 1 presents the age of the participants; most participants quinolones.
(33.3%) aged 20 – 30 years, while the smallest percentage (0.3%) 4. Discussion
aged over 70 years. Moreover, female participants slightly
outnumbered male participants (50.3% vs. 49.7%, respectively). Vonoprazan was just recently brought to the Egyptian market
There were also more naïve patients than experienced patients in early 2022, though it has been available in Japan and a few
(58.5% vs. 41.5%, respectively). other nations since 2015. This is the first multicentric Egyptian
Table 2 indicates that vonoprazan-based treatment study of vonoprazan triple therapy for H. pylori.
outperformed omeprazole-based therapy in eradicating H. pylori Standard triple treatment (STT) with PPIs, AMO, and CLA
in both naïve (P < 0.001) and experienced (P = 0.001) patients. is unsuccessful in many countries due to H. pylori developing
However, vonoprazan-based treatment did not significantly CLA resistance. Four-drug combinations, such as bismuth-
vary between naïve and experienced groups (p = 0.504). containing quadruple therapy (BQT) or concurrent quadruple
0
Table 3 documents the adverse events experienced by therapy, are first-line therapies for such diseases [27,28].
patients. From the 598 vonoprazan-treated patients, five reported In previous studies, the eradication rates were 55 – 72% for
nausea/vomiting, ten with diarrhea, eight with constipation, two STT within 7 days [25,29], 80 – 95% for BQT [30,31], and
with bloating, and six with rashes, but none of them were severe. 86 – 91% for concomitant quadruple therapy (CQT) [32] as first-

Table 1. Distribution of the studied cases according to different parameters (n=1184)
Parameter Number of patients (%) Test of significance P‑value
Total (n=1184) (%) Group I (n=586) (%) Group II (n=598) (%)
Age (years)
20 – 30 394 (33.3) 203 (34.6) 191 (31.9) χ =7.934 0.160
2
31 – 40 353 (29.8) 179 (30.5) 174 (29.1)
41 – 50 236 (19.9) 120 (20.5) 116 (19.4)
51 – 60 149 (12.6) 63 (10.8) 86 (14.4)
61 – 70 49 (4.1) 21 (3.6) 28 (4.7)
>70 3 (0.3) 0 (0) 3 (0.5)
Sex
2
Male 589 (49.7) 300 (51.2) 289 (48.3) χ =0.973 0.324
Female 595 (50.3) 286 (48.8) 309 (51.0)
Weight (kg)
Min-Max 69.0 – 121.0 69.0 – 121.0 69.0 – 121.0 t=0.672 0.502
Mean±SD 92.13±15.0 92.72±14.84 92.13±15.0
Median (IQR) 95.0 (78 – 105) 96.0 (78 – 105) 95.0 (78 – 105)
Height (cm)
Min–Max 150.0 – 188.0 150.0 – 188.0 150.0 – 188.0 t=0.034 0.973
Mean±SD 170.06±10.67 170.0±10.59 170.1±10.67
Median (IQR) 172.0 (161 – 180) 172.0 (161 – 179) 172.0 (161 – 180)
2
χ refers to the Chi-square test; t refers to Student’s t-test; p refers to the p-value obtained from comparing groups I and II. Abbreviations: SD: Standard deviation; IQR: Interquartile range
Table 2. Comparison between omeprazole- and vonoprazan-based therapy in naïve and experienced patients
Patients Number of patients (%) P p 0
Omeprazole (%) Vonoprazan (%) Omeprazole Vonoprazan
Naïve (n=701) 0.293 0.504
Positive 88 (25.4) 32 (9.0) <0.001*
Negative 258 (74.6) 323 (91.0)
Experienced (n=483)
Positive 52 (21.7) 25 (10.3) 0.001*
Negative 188 (78.3) 218 (89.7)
“Positive” and “Negative” refer to the drug effect experienced by the patients; P denotes P-value from the Chi-square test comparing omeprazole- and vonoprazan-based therapy; p denotes
0
P-value from the Chi-square test comparing naïve and experienced patients; *denotes statistical significance at P<0.05
DOI: http://doi.org/10.36922/jctr.24.00043